ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

ClinicalTrials.gov ID: NCT04991571

Public ClinicalTrials.gov record NCT04991571. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-label Study With Two Independent Parts: Collecting Samples for Metabolites in Safety Testing Analysis of Zibotentan After Repeated Administration (Part 1); and a Randomised, Cross-over, Three Period, Three-treatment, Single Dose Study to Assess the Relative Bioavailability of Different Formulations of Zibotentan and Dapagliflozin (Part 2) in Healthy Adult Participants

Study identification

NCT ID
NCT04991571
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
AstraZeneca
Industry
Enrollment
27 participants

Conditions and interventions

Interventions

  • Dapagliflozin (Treatment A) Drug
  • Zibotentan (Treatment A) Drug
  • Zibotentan/Dapagliflozin - Formulation 1 (Treatment B) Drug
  • Zibotentan/Dapagliflozin - Formulation 2 (Treatment C) Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 28, 2021
Primary completion
Oct 21, 2021
Completion
Oct 21, 2021
Last update posted
Nov 22, 2021

2021

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Research Site Brooklyn Maryland 21225 โ€”

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04991571, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 22, 2021 ยท Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04991571 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record โ†’